ATE214936T1 - Oxidiertes glutathion als mittel zur verbesserung der endogenen produktion von cytokinen und haematopoietischen faktoren - Google Patents
Oxidiertes glutathion als mittel zur verbesserung der endogenen produktion von cytokinen und haematopoietischen faktorenInfo
- Publication number
- ATE214936T1 ATE214936T1 AT96941915T AT96941915T ATE214936T1 AT E214936 T1 ATE214936 T1 AT E214936T1 AT 96941915 T AT96941915 T AT 96941915T AT 96941915 T AT96941915 T AT 96941915T AT E214936 T1 ATE214936 T1 AT E214936T1
- Authority
- AT
- Austria
- Prior art keywords
- pharmaceutically acceptable
- oxidized glutathione
- salt form
- acceptable salt
- production
- Prior art date
Links
- 108010053070 Glutathione Disulfide Proteins 0.000 title abstract 5
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 title abstract 5
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 title abstract 5
- 102000004127 Cytokines Human genes 0.000 title abstract 3
- 108090000695 Cytokines Proteins 0.000 title abstract 3
- 230000003394 haemopoietic effect Effects 0.000 title 1
- 150000003839 salts Chemical group 0.000 abstract 4
- 230000002607 hemopoietic effect Effects 0.000 abstract 2
- 239000004606 Fillers/Extenders Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU95120403/14A RU2089179C1 (ru) | 1995-12-14 | 1995-12-14 | Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования |
| PCT/RU1996/000226 WO1997021443A1 (en) | 1995-12-14 | 1996-08-08 | Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof |
| PCT/RU1996/000340 WO1997021444A1 (en) | 1995-12-14 | 1996-12-10 | Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE214936T1 true ATE214936T1 (de) | 2002-04-15 |
Family
ID=26653679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96941915T ATE214936T1 (de) | 1995-12-14 | 1996-12-10 | Oxidiertes glutathion als mittel zur verbesserung der endogenen produktion von cytokinen und haematopoietischen faktoren |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0869809B1 (enExample) |
| JP (2) | JP2000515111A (enExample) |
| AT (1) | ATE214936T1 (enExample) |
| AU (1) | AU1113097A (enExample) |
| CA (1) | CA2239874A1 (enExample) |
| DE (1) | DE69620233T2 (enExample) |
| ES (1) | ES2174124T3 (enExample) |
| WO (1) | WO1997021444A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040101576A1 (en) * | 1997-03-21 | 2004-05-27 | Eiichiro Yagi | Immunopotentiators |
| IL123887A0 (en) * | 1997-04-02 | 1998-10-30 | Sankyo Co | Dithiolan derivatives their use and pharmaceutical compositions containing the same |
| US6399372B1 (en) | 1998-03-30 | 2002-06-04 | I.D.M. Immuno-Designed | Monocyte derived cells with immunostimulating properties, their preparation and uses |
| JP2000169371A (ja) * | 1998-10-02 | 2000-06-20 | Sankyo Co Ltd | ジチオラン誘導体を含有する医薬 |
| US6312734B1 (en) * | 1998-11-23 | 2001-11-06 | Novelos Therapeutics, Inc. | Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells |
| RU2144374C1 (ru) | 1998-11-23 | 2000-01-20 | Закрытое акционерное общество "ВАМ" | Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток |
| US20070142267A1 (en) | 1998-11-23 | 2007-06-21 | Novelos Therapeutics, Inc. | Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells |
| RU2229892C2 (ru) * | 2001-06-08 | 2004-06-10 | Государственное учреждение "Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии" | Способ лечения туберкулеза легких |
| US7173013B2 (en) | 2001-06-08 | 2007-02-06 | Sciclone Pharmaceuticals, Inc. | Treatment of tuberculosis using immunomodulator compounds |
| JP2006515629A (ja) * | 2003-01-23 | 2006-06-01 | シャイア ラボラトリーズ，インコーポレイテッド | 吸収促進剤 |
| RU2482868C1 (ru) * | 2011-12-30 | 2013-05-27 | Общество С Ограниченной Ответственностью "Ива Фарм" | Средство для лечения диабета, фармацевтическая композиция и способ лечения заболеваний |
| JP6469568B2 (ja) * | 2012-09-28 | 2019-02-13 | 協和発酵バイオ株式会社 | グルタチオンを含有する免疫増強剤 |
| RU2545900C2 (ru) * | 2013-05-07 | 2015-04-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук | Способ диагностики апоптоза лимфоцитов |
| RU2540500C2 (ru) * | 2013-05-07 | 2015-02-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук | Способ прогнозирования ранней стадии апоптоза |
| RU2659161C1 (ru) | 2017-11-17 | 2018-06-28 | Общество С Ограниченной Ответственностью "Ива Фарм" | Фармацевтическая композиция, включающая дисульфид глутатиона и глутатион дисульфид s-оксид |
| CN114617899B (zh) * | 2022-04-14 | 2023-10-20 | 苏州大学附属儿童医院 | S-腺苷甲硫氨酸在制备治疗脓毒血症相关性脑病药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61277619A (ja) * | 1985-06-04 | 1986-12-08 | Otsuka Pharmaceut Factory Inc | 肝疾患治療剤 |
| JP2921124B2 (ja) * | 1990-12-28 | 1999-07-19 | 千寿製薬株式会社 | 酸化型グルタチオンアルキルエステル |
| US5977073A (en) * | 1991-06-06 | 1999-11-02 | Life Sciences' Technologies, Inc. | Nutrient composition for treatment of immune disorders |
| US5618823A (en) * | 1992-06-24 | 1997-04-08 | Boehringer Mannheim Italia S.P.A. | Glutathione as chemoprotective agent |
| GB9303854D0 (en) * | 1993-02-25 | 1993-04-14 | Holt John A G | Method for enhancing t-cell count |
-
1996
- 1996-12-10 AU AU11130/97A patent/AU1113097A/en not_active Abandoned
- 1996-12-10 DE DE69620233T patent/DE69620233T2/de not_active Expired - Lifetime
- 1996-12-10 ES ES96941915T patent/ES2174124T3/es not_active Expired - Lifetime
- 1996-12-10 JP JP09521965A patent/JP2000515111A/ja not_active Withdrawn
- 1996-12-10 EP EP96941915A patent/EP0869809B1/en not_active Expired - Lifetime
- 1996-12-10 WO PCT/RU1996/000340 patent/WO1997021444A1/en not_active Ceased
- 1996-12-10 CA CA002239874A patent/CA2239874A1/en not_active Abandoned
- 1996-12-10 AT AT96941915T patent/ATE214936T1/de active
-
2007
- 2007-09-13 JP JP2007238577A patent/JP2008001722A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE69620233D1 (de) | 2002-05-02 |
| WO1997021444A1 (en) | 1997-06-19 |
| ES2174124T3 (es) | 2002-11-01 |
| DE69620233T2 (de) | 2002-11-14 |
| JP2000515111A (ja) | 2000-11-14 |
| EP0869809B1 (en) | 2002-03-27 |
| EP0869809A1 (en) | 1998-10-14 |
| JP2008001722A (ja) | 2008-01-10 |
| AU1113097A (en) | 1997-07-03 |
| CA2239874A1 (en) | 1997-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE214936T1 (de) | Oxidiertes glutathion als mittel zur verbesserung der endogenen produktion von cytokinen und haematopoietischen faktoren | |
| Skinner et al. | A preliminary study of the effects of laser radiation on collagen metabolism in cell culture | |
| GEP20002146B (en) | Therapeutic Peptide Derivatives | |
| EP0209689A3 (en) | Use of tetrahydrobiopterins in the treatment of infantile autism | |
| BR8804370A (pt) | Dispositivo eletroterapeutico de baixa frequencia | |
| DE69722426D1 (de) | Isobutylgaba und dessen derivate zur schmerzbehandlung | |
| ATE227587T1 (de) | Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts | |
| DE3877529D1 (de) | Herstellung von hoch-gereingtem menschlichen faktor ix sowie anderem plasmaproteinkonzentrat und dessen therapeutische verwendung. | |
| DE69735581D1 (de) | Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung | |
| ZA981609B (en) | Method of treating a tumor | |
| PT1119393E (pt) | Estimulacao electromagnetica de tecido de cartilagem utilizando fgf | |
| DE69621243D1 (de) | Verwendung von bradykininantagonisten zur induzierung oder stimulation des haarwachstums und/oder zur verlangsamung des haarausfalls | |
| ATE393631T1 (de) | Peptid und dessen kosmetische oder dermatologische verwendung zur verbesserung der haftung zwischen hautzellen | |
| IT1258069B (it) | Composizione per uso topico avente attivita' di stimolo per la ricrescita, di rinvigorimento, di prevenzione dell'ingrigimento e di ripigmentazione naturale dei capelli | |
| ATE198271T1 (de) | Syndecan-stimulierung der zellulären differenzierung | |
| DE69110615D1 (de) | Verwendung von Aminosäuren zum Schutz von ischemischem Herzgewebe und dessen metabolischer Wiederherstellung. | |
| DE60032143D1 (de) | Verwendung von eif4e-bindungsreagenzien in der therapie | |
| GEP20012377B (en) | Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases | |
| RU94024337A (ru) | Антиметастатическое средство | |
| DE69725312D1 (de) | Verbesserte elektrophoretische verabreichung von therapeutischen wirkstoffen mit polybasischen anionischen gegenionen | |
| RU2002113429A (ru) | Способ лечения псориаза | |
| GB0202410D0 (en) | Treatment of IL deficiencies | |
| PT859630E (pt) | Combinacao de temozolomida e alfa-ifn no tratamento de cancro avancado | |
| RU97121729A (ru) | Способ стимуляции репаративного остеогенеза | |
| UA39768A (uk) | Спосіб лікування хворих зі спазмом акомодації |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |